{
    "2020-08-04": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Incyte Earnings Soar 65%, Easily Beating Views",
                "features": {
                    "keywords": [
                        "Earnings",
                        "Soar",
                        "Beating Views"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "3 Stocks With Low Forward Price-Earnings Ratios",
                "features": {
                    "keywords": [
                        "Low",
                        "Forward",
                        "Price-Earnings Ratios"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans",
                "features": {
                    "keywords": [
                        "End Collaboration",
                        "Thumbs Down",
                        "Expedites",
                        "Trial Plans"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis announces KymriahÂ® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma",
                "features": {
                    "keywords": [
                        "Kymriah",
                        "Meets",
                        "Primary Endpoint",
                        "Pivotal Study"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}